Biotechnology Following a study published in The Lancet Oncology regarding a brand new type of cancer drug that has shown promise in multiple cancer types in early Phase I/II trials, Philippa Salter, pharma analyst at data and analytics firm GlobalData, offers her views, nothing that “although cancer treatment has significantly advanced over the past few decades, there are still many ‘difficult-to-treat’ cancers, particularly when they reach more advanced stages.” 13 February 2019